Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AEON Biopharma, Inc. (AEON) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing structured access to its regulatory and financial reporting. AEON is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) injection as a proposed BOTOX biosimilar for therapeutic indications under the FDA’s 351(k) biosimilar pathway. Its filings offer detailed insight into this development strategy, capital structure, and governance.
Key documents include Form 8-K current reports describing material events such as the Securities Purchase Agreement for a PIPE private placement, the Exchange Agreement with Daewoong Pharmaceutical to convert senior secured convertible notes into equity, a new note due 2030, and warrants, and updates on corporate presentations made available to investors. These filings explain terms of new securities, warrant structures, conversion mechanics, and conditions tied to stockholder approval and NYSE American rules.
AEON’s definitive proxy statement on Schedule 14A details proposals for a special meeting of stockholders, including approval of the PIPE financing, the Daewoong note exchange, and amendments to the company’s incentive award plan. This proxy statement outlines how these transactions relate to funding the development and potential commercialization of ABP-450 as a biosimilar to BOTOX, and describes voting procedures and board recommendations.
Periodic filings referenced in the company’s 8-Ks, such as its Form 10-K for the fiscal year ended December 31, 2024, provide broader context on risk factors, forward-looking statements, and financial reporting policies. AEON’s 8-Ks also furnish quarterly earnings press releases, which include condensed consolidated financial statements and discussions of operating expenses, research and development spending, and changes in fair value of financial instruments.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in lengthy documents, helping users quickly understand complex topics like convertible note exchanges, warrant anti-dilution provisions, and biosimilar regulatory milestones. Real-time updates from EDGAR ensure that new forms—whether 8-Ks, proxy statements, or annual and quarterly reports—are available promptly. Users can also track equity-related disclosures, including inducement grants and incentive plan changes, to better understand AEON’s governance and compensation practices.
Bencich John reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that Chief Financial Officer John Bencich received a grant of 754,717 shares of Class A common stock in the form of restricted stock units. The award was granted on April 1, 2026 and carries no purchase price per share.
The restricted stock units vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date, contingent on continued service through each vesting date. Following this award, Bencich is shown as directly owning 754,717 shares of Class A common stock.
AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich. This filing is a Form 3, which serves as the starting disclosure of his beneficial ownership in AEON as an officer. The report does not list any specific transactions or share movements.
AEON Biopharma, Inc. reported that NYSE American sent an additional notice stating the company no longer meets an extra continued listing standard. The exchange requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years.
AEON instead reported a stockholders’ deficit of approximately $55 million as of December 31, 2025, along with losses in three of its four most recent fiscal years. The company is already operating under a previously accepted plan to regain compliance by August 3, 2026.
The new notice does not immediately affect trading of AEON’s Class A common stock, which will continue to list on NYSE American with a “.BC” below‑compliance indicator and inclusion on the noncompliant issuers list. If AEON fails to regain compliance by August 3, 2026, NYSE American may begin delisting proceedings, which AEON would have the right to appeal.
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing ABP-450 as a biosimilar to Botox for all approved therapeutic indications in the U.S. under the FDA’s Section 351(k) pathway. The company holds exclusive therapeutic rights to ABP-450 across the U.S., Canada, the EU, the U.K. and certain other territories and is targeting the roughly $3.3 billion U.S. therapeutic botulinum toxin market, which is projected to grow about 8% annually and is dominated by Botox.
ABP-450 is the same 900 kDa botulinum toxin complex marketed cosmetically as Jeuveau/Nuceiva and is manufactured by Daewoong in cGMP-inspected facilities. AEON is pursuing an “analytical-first” biosimilar strategy, has held multiple FDA biosimilar program (BPD) meetings, and plans to complete most analytical comparability work in 2026 before moving to the next phase of development.
The company emphasizes potential full-label clinical substitutability with Botox and a differentiated, therapy-only BLA structure that could support distinct reimbursement economics in buy-and-bill settings. However, AEON has never been profitable and reported an accumulated deficit of $470.8 million as of December 31, 2025. Management concludes there is substantial doubt about AEON’s ability to continue as a going concern without additional financing, expecting its current cash (including $4.2 million from a January 2026 closing) to fund operations only into the third quarter of 2026.
AEON Biopharma reported a sharp swing to loss for 2025 while advancing its ABP-450 biosimilar program and repairing its balance sheet. For the year ended December 31, 2025, net loss was $39,222 thousand, compared with net income of $42,005 thousand in 2024, driven largely by volatile fair value and warrant-related items.
Total operating costs and expenses were $12,803 thousand, versus $(72,985) thousand in 2024, when a large non-cash reduction in contingent consideration had boosted results. AEON ended 2025 with cash and cash equivalents of $3,006 thousand, total liabilities of $60,587 thousand, and a stockholders’ deficit of $55,027 thousand, highlighting a highly leveraged capital structure.
Strategically, the company reported positive initial analytical biosimilarity data for ABP-450 versus BOTOX, a favorable FDA BPD Type 2a meeting outlining a clear analytical path, and a $6 million PIPE financing and Daewoong note exchange that reduced outstanding debt by more than 90%.
AEON Biopharma, Inc. chief medical officer Chad Oh reported receiving equity awards of Class A common stock as compensation. On February 17, 2026, he was granted 862,500 restricted stock units that vest in four substantially equal annual installments, starting on the first anniversary of the grant date, subject to continued service.
On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash upon vesting, while keeping the same four-year vesting schedule from the 2025 grant date. After these awards, his direct holdings increased to 2,183,436 shares of Class A common stock. These are compensation-related acquisitions, not open-market purchases or sales.
AEON Biopharma appointed John Bencich as Chief Financial Officer effective March 9, 2026, and principal financial officer effective April 1, 2026, as part of a plan to strengthen its leadership during key regulatory and financing milestones. He brings more than 25 years of biotechnology and life sciences finance experience, including prior CEO, COO and CFO roles at several public and private companies.
His employment agreement provides a $450,000 base salary, a 40% target cash bonus opportunity, severance protections, and equity inducement grants of 754,717 restricted stock units and 235,849 performance-based restricted stock units under AEON’s 2025 Employment Inducement Incentive Award Plan. AEON also entered into a new employment agreement with Chief Accounting Officer Jennifer Sy, maintaining her existing pay and bonus targets while formalizing severance and change-in-control protections. The Board amended the Inducement Plan to reserve an additional 1,000,000 shares of Class A common stock for future equity awards.
AEON Biopharma, Inc. reported that executive Wilson Alexander Blair, its CLO, CSO and Corporate Secretary, acquired Class A common stock through equity compensation awards rather than open-market purchases.
On February 17, 2026, he received an award of 862,500 restricted stock units, vesting in substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service. On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash, with the original four-year vesting schedule maintained. Both transactions were reported at a price of $0.00 per share and are classified as direct ownership, bringing Blair’s total directly held Class A shares to 2,183,005 after the March 4 transaction.
AEON Biopharma, Inc. reported that its principal accounting officer, Jennifer Sy, acquired Class A common stock through equity awards. On February 17, 2026, she received an award of 575,000 restricted stock units that vest in substantially equal installments over four years, subject to continued service. On March 4, 2026, 925,925 previously granted cash-settled restricted stock units from May 21, 2025 were modified to be settled in stock instead of cash, while retaining the same four-year vesting schedule.
Bancroft Robert E. reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that President and CEO Robert E. Bancroft received a grant of 3,000,000 shares of Class A Common Stock in the form of restricted stock units on February 17, 2026. The award was granted at a price of $0.00 per share.
These restricted stock units vest in substantially equal installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to his continued service. Following this award, his directly held Class A Common Stock stake reported in this filing is 3,177,103 shares.